Download PDF
Semin Liver Dis 2009; 29(4): 337-347
DOI: 10.1055/s-0029-1240002
© Thieme Medical Publishers

Epidemiology of Idiosyncratic Drug-Induced Liver Injury

Lauren N. Bell1 , Naga Chalasani1
  • 1Divisions of Gastroenterology/Hepatology and Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana
Further Information

Publication History

Publication Date:
13 October 2009 (online)

    Permissions and Reprints

ABSTRACT

Idiosyncratic drug-induced liver injury (DILI) is a significant health problem because of its unpredictable nature, poorly understood pathogenesis, and potential to cause fatal outcomes. It is also a significant hurdle for drug development and marketing of safe prescription medications. Idiosyncratic DILI is generally rare, but its occurrence is likely underappreciated due to the lack of active reporting or surveillance systems and substantial challenges involved in its recognition and diagnosis. Nonetheless, DILI is a common cause of potentially serious and fatal acute liver failure in both children and adults. Population-based studies that accurately estimate the incidence and full spectrum of DILI are limited. However, using a prospective, population-based French study with an annual estimated incidence of 13.9 ± 2.4 DILI cases per 100,000 inhabitants, it has been extrapolated that nearly 44,000 individuals in the United States will suffer from DILI each year. Although increasing numbers of patients are also being seen with DILI due to herbal and dietary supplements, the epidemiology of this entity requires further investigation. In this article, the epidemiology of DILI, both in the general population and in potentially high-risk subgroups, is reviewed.

KEYWORDS

Idiosyncratic - hepatotoxicity - acute liver failure - adverse drug reaction

REFERENCES

  • 1 Ostapowicz G, Fontana R J, Schiødt F V U.S. Acute Liver Failure Study Group et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States.  Ann Intern Med. 2002;  137(12) 947-954
    CrossrefPubMedGoogle Scholar
  • 2 Watkins P B, Seeff L B. Drug-induced liver injury: summary of a single topic clinical research conference.  Hepatology. 2006;  43(3) 618-631
    CrossrefPubMedGoogle Scholar
  • 3 Navarro V J, Senior J R. Drug-related hepatotoxicity.  N Engl J Med. 2006;  354(7) 731-739
    CrossrefPubMedGoogle Scholar
  • 4 Abboud G, Kaplowitz N. Drug-induced liver injury.  Drug Saf. 2007;  30(4) 277-294
    CrossrefPubMedGoogle Scholar
  • 5 Lazarou J, Pomeranz B H, Corey P N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.  JAMA. 1998;  279(15) 1200-1205
    Google Scholar
  • 6 Murray K F, Hadzic N, Wirth S, Bassett M, Kelly D. Drug-related hepatotoxicity and acute liver failure.  J Pediatr Gastroenterol Nutr. 2008;  47(4) 395-405
    CrossrefPubMedGoogle Scholar
  • 7 Nourjah P, Ahmad S R, Karwoski C, Willy M. Estimates of acetaminophen (paracetomal)-associated overdoses in the United States.  Pharmacoepidemiol Drug Saf. 2006;  15(6) 398-405
    CrossrefPubMedGoogle Scholar
  • 8 Rowden A K, Norvell J, Eldridge D L, Kirk M A. Updates on acetaminophen toxicity.  Med Clin North Am. 2005;  89(6) 1145-1159
    CrossrefPubMedGoogle Scholar
  • 9 Lee W M. Acetaminophen toxicity: changing perceptions on a social/medical issue.  Hepatology. 2007;  46(4) 966-970
    CrossrefPubMedGoogle Scholar
  • 10 Larson A M, Polson J, Fontana R J Acute Liver Failure Study Group et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study.  Hepatology. 2005;  42(6) 1364-1372
    CrossrefPubMedGoogle Scholar
  • 11 Fontana R J. Acute liver failure due to drugs.  Semin Liver Dis. 2008;  28(2) 175-187
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Andrade R J, Robles M, Fernández-Castañer A, López-Ortega S, López-Vega M C, Lucena M I. Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists.  World J Gastroenterol. 2007;  13(3) 329-340
    PubMedGoogle Scholar
  • 13 De Valle M B, Av Klinteberg V, Alem N, Olsson R, Björnsson E. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic.  Aliment Pharmacol Ther. 2006;  24(8) 1187-1195
    CrossrefPubMedGoogle Scholar
  • 14 Hussaini S H, O'Brien C S, Despott E J, Dalton H R. Antibiotic therapy: a major cause of drug-induced jaundice in southwest England.  Eur J Gastroenterol Hepatol. 2007;  19(1) 15-20
    CrossrefPubMedGoogle Scholar
  • 15 Meier Y, Cavallaro M, Roos M et al.. Incidence of drug-induced liver injury in medical inpatients.  Eur J Clin Pharmacol. 2005;  61(2) 135-143
    CrossrefPubMedGoogle Scholar
  • 16 Russo M W, Galanko J A, Shrestha R, Fried M W, Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States.  Liver Transpl. 2004;  10(8) 1018-1023
    CrossrefPubMedGoogle Scholar
  • 17 Vuppalanchi R, Liangpunsakul S, Chalasani N. Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States?.  Am J Gastroenterol. 2007;  102(3) 558-562, quiz 693
    CrossrefPubMedGoogle Scholar
  • 18 Jinjuvadia K, Kwan W, Fontana R J. Searching for a needle in a haystack: use of ICD-9-CM codes in drug-induced liver injury.  Am J Gastroenterol. 2007;  102(11) 2437-2443
    CrossrefPubMedGoogle Scholar
  • 19 Duh M S, Walker A M, Kronlund Jr K H. Descriptive epidemiology of acute liver enzyme abnormalities in the general population of central Massachusetts.  Pharmacoepidemiol Drug Saf. 1999;  8(4) 275-283
    CrossrefPubMedGoogle Scholar
  • 20 de Abajo F J, Montero D, Madurga M, García Rodríguez L A. Acute and clinically relevant drug-induced liver injury: a population based case-control study.  Br J Clin Pharmacol. 2004;  58(1) 71-80
    CrossrefPubMedGoogle Scholar
  • 21 Hartleb M, Biernat L, Kochel A. Drug-induced liver damage—a three-year study of patients from one gastroenterological department.  Med Sci Monit. 2002;  8(4) CR292-CR296
    PubMedGoogle Scholar
  • 22 Andrade R J, Lucena M I, Fernández M C Spanish Group for the Study of Drug-Induced Liver Disease et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period.  Gastroenterology. 2005;  129(2) 512-521
    CrossrefPubMedGoogle Scholar
  • 23 Chalasani N, Fontana R J, Bonkovsky H L Drug Induced Liver Injury Network (DILIN) et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.  Gastroenterology. 2008;  135(6) 1924-1934, 1934.e1–e4
    CrossrefPubMedGoogle Scholar
  • 24 Hoofnagle J H. Drug-induced liver injury network (DILIN).  Hepatology. 2004;  40(4) 773
    PubMedGoogle Scholar
  • 25 Sgro C, Clinard F, Ouazir K et al.. Incidence of drug-induced hepatic injuries: a French population-based study.  Hepatology. 2002;  36(2) 451-455
    CrossrefPubMedGoogle Scholar
  • 26 Takikawa H, Murata Y, Horiike N, Fukui H, Onji M. Drug-induced liver injury in Japan: an analysis of 1676 cases between 1997 and 2006.  Hepatol Res. 2009;  39(5) 427-431
    PubMedGoogle Scholar
  • 27 Tameda T, Adachi Y, Watanabe A. National survey of drug-induced liver injury. In: Watanabe A, Higuchi K Newest Hepatology. Tokyo; Shinko-Igaku 2001: 50-61
    PubMedGoogle Scholar
  • 28 Wai C T, Tan B H, Chan C L et al.. Drug-induced liver injury at an Asian center: a prospective study.  Liver Int. 2007;  27(4) 465-474
    CrossrefPubMedGoogle Scholar
  • 29 Shapiro M A, Lewis J H. Causality assessment of drug-induced hepatotoxicity: promises and pitfalls.  Clin Liver Dis. 2007;  11(3) 477-505, v
    CrossrefPubMedGoogle Scholar
  • 30 Lucena M I, Andrade R J, Kaplowitz N Spanish Group for the Study of Drug-Induced Liver Disease et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex.  Hepatology. 2009;  49(6) 2001-2009
    CrossrefPubMedGoogle Scholar
  • 31 Elinav E, Pinsker G, Safadi R et al.. Association between consumption of Herbalife nutritional supplements and acute hepatotoxicity.  J Hepatol. 2007;  47(4) 514-520
    CrossrefPubMedGoogle Scholar
  • 32 García-Cortés M, Borraz Y, Lucena M I et al.. [Liver injury induced by “natural remedies”: an analysis of cases submitted to the Spanish Liver Toxicity Registry].  Rev Esp Enferm Dig. 2008;  100(11) 688-695
    PubMedGoogle Scholar
  • 33 Ibáñez L, Pérez E, Vidal X, Laporte J R. Grup d'Estudi Multicènteric d'Hepatotoxicitat Aguda de Barcelona (GEMHAB) . Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs.  J Hepatol. 2002;  37(5) 592-600
    CrossrefPubMedGoogle Scholar
  • 34 Abebe W. Herbal medication: potential for adverse interactions with analgesic drugs.  J Clin Pharm Ther. 2002;  27(6) 391-401
    CrossrefPubMedGoogle Scholar
  • 35 Estes J D, Stolpman D, Olyaei A et al.. High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure.  Arch Surg. 2003;  138(8) 852-858
    CrossrefPubMedGoogle Scholar
  • 36 Schenker S, Bay M. Drug disposition and hepatotoxicity in the elderly.  J Clin Gastroenterol. 1994;  18(3) 232-237
    CrossrefPubMedGoogle Scholar
  • 37 Fountain F F, Tolley E, Chrisman C R, Self T H. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic.  Chest. 2005;  128(1) 116-123
    CrossrefPubMedGoogle Scholar
  • 38 Grönhagen-Riska C, Hellstrom P E, Fröseth B. Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis.  Am Rev Respir Dis. 1978;  118(3) 461-466
    PubMedGoogle Scholar
  • 39 Onji M, Fujioka S, Takeuchi Y et al.. Clinical characteristics of drug-induced liver injury in the elderly.  Hepatol Res. 2009;  39(6) 546-552
    PubMedGoogle Scholar
  • 40 Pelkonen O, Turpeinen M, Hakkola J, Honkakoski P, Hukkanen J, Raunio H. Inhibition and induction of human cytochrome P450 enzymes: current status.  Arch Toxicol. 2008;  82(10) 667-715
    CrossrefPubMedGoogle Scholar
  • 41 Lucena M I, Andrade R J, Fernández M C Spanish Group for the Study of Drug-Induced Liver Disease (Grupo de Estudio para las Hepatopatías Asociadas a Medicamentos (GEHAM)) et al. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain.  Hepatology. 2006;  44(4) 850-856
    CrossrefPubMedGoogle Scholar
  • 42 Squires Jr R HJ, Shneider B L, Bucuvalas J et al.. Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group.  J Pediatr. 2006;  148(5) 652-658
    CrossrefPubMedGoogle Scholar
  • 43 Maddrey W C. Drug-induced hepatotoxicity: 2005.  J Clin Gastroenterol. 2005;  39(4, Suppl 2) S83-S89
    CrossrefPubMedGoogle Scholar
  • 44 Soriano V, Puoti M, Garcia-Gascó P et al.. Antiretroviral drugs and liver injury.  AIDS. 2008;  22(1) 1-13
    CrossrefPubMedGoogle Scholar
  • 45 Núñez M J, Martín-Carbonero L, Moreno V et al.. Impact of antiretroviral treatment-related toxicities on hospital admissions in HIV-infected patients.  AIDS Res Hum Retroviruses. 2006;  22(9) 825-829
    CrossrefPubMedGoogle Scholar
  • 46 Akhtar A J, Shaheen M. Jaundice in African-American and Hispanic patients with AIDS.  J Natl Med Assoc. 2007;  99(12) 1381-1385
    PubMedGoogle Scholar
  • 47 Ungo J R, Jones D, Ashkin D et al.. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus.  Am J Respir Crit Care Med. 1998;  157(6 Pt 1) 1871-1876
    CrossrefPubMedGoogle Scholar
  • 48 Tostmann A, Boeree M J, Aarnoutse R E, de Lange W C, van der Ven A J, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review.  J Gastroenterol Hepatol. 2008;  23(2) 192-202
    CrossrefPubMedGoogle Scholar
  • 49 Núñez M, Lana R, Mendoza J L, Martín-Carbonero L, Soriano V. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy.  J Acquir Immune Defic Syndr. 2001;  27(5) 426-431
    PubMedGoogle Scholar
  • 50 Sulkowski M S, Thomas D L, Chaisson R E, Moore R D. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection.  JAMA. 2000;  283(1) 74-80
    CrossrefPubMedGoogle Scholar
  • 51 Rodríguez-Rosado R, García-Samaniego J, Soriano V. Hepatotoxicity after introduction of highly active antiretroviral therapy.  AIDS. 1998;  12(10) 1256
    CrossrefPubMedGoogle Scholar
  • 52 Savès M, Vandentorren S, Daucourt V et al.. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996–1998. Groupe dEpidémiologie Clinique de Sida en Aquitaine (GECSA).  AIDS. 1999;  13(17) F115-F121
    CrossrefPubMedGoogle Scholar
  • 53 Savès M, Raffi F, Clevenbergh P The APROCO Study Group et al. Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients.  Antimicrob Agents Chemother. 2000;  44(12) 3451-3455
    CrossrefPubMedGoogle Scholar
  • 54 Bonfanti P, Landonio S, Ricci E CISAI study group et al. Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy.  J Acquir Immune Defic Syndr. 2001;  27(3) 316-318
    CrossrefPubMedGoogle Scholar
  • 55 Monforte Ade A, Bugarini R, Pezzotti P ICONA (Italian Cohort of Naive for Antiretrovirals) Study Group et al. Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART.  J Acquir Immune Defic Syndr. 2001;  28(2) 114-123
    CrossrefPubMedGoogle Scholar
  • 56 Aceti A, Pasquazzi C, Zechini B, De Bac C. LIVERHAART Group . Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection.  J Acquir Immune Defic Syndr. 2002;  29(1) 41-48
    PubMedGoogle Scholar
  • 57 Wit F W, Weverling G J, Weel J, Jurriaans S, Lange J M. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy.  J Infect Dis. 2002;  186(1) 23-31
    CrossrefPubMedGoogle Scholar
  • 58 Servoss J C, Kitch D W, Andersen J W, Reisler R B, Chung R T, Robbins G K. Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989–1999).  J Acquir Immune Defic Syndr. 2006;  43(3) 320-323
    CrossrefPubMedGoogle Scholar
  • 59 Núñez M, Ríos P, Martín-Carbonero L, Pérez-Olmeda M, González-Lahoz J, Soriano V. Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy.  J Acquir Immune Defic Syndr. 2002;  30(1) 65-68
    CrossrefPubMedGoogle Scholar
  • 60 Maida I, Babudieri S, Selva C et al.. Liver enzyme elevation in hepatitis C virus (HCV)-HIV-coinfected patients prior to and after initiating HAART: role of HCV genotypes.  AIDS Res Hum Retroviruses. 2006;  22(2) 139-143
    CrossrefPubMedGoogle Scholar
  • 61 Torti C, Lapadula G, Puoti M et al.. Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER Cohort.  J Acquir Immune Defic Syndr. 2006;  41(2) 180-185
    CrossrefPubMedGoogle Scholar
  • 62 Aranzabal L, Casado J L, Moya J et al.. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.  Clin Infect Dis. 2005;  40(4) 588-593
    CrossrefPubMedGoogle Scholar
  • 63 Zimmerman H J. Hepatotoxicity. The Adverse Effects of Drugs and Other Chemicals on the Liver, 2nd ed. Philadelphia, PA; Lippincott Williams & Wilkins 1999
    PubMedGoogle Scholar
  • 64 Wong W M, Wu P C, Yuen M F et al.. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection.  Hepatology. 2000;  31(1) 201-206
    CrossrefPubMedGoogle Scholar
  • 65 Wu J C, Lee S D, Yeh P F et al.. Isoniazid-rifampin-induced hepatitis in hepatitis B carriers.  Gastroenterology. 1990;  98(2) 502-504
    PubMedGoogle Scholar
  • 66 Gupta N K, Lewis J H. Review article: The use of potentially hepatotoxic drugs in patients with liver disease.  Aliment Pharmacol Ther. 2008;  28(9) 1021-1041
    CrossrefPubMedGoogle Scholar
  • 67 Labarga P, Soriano V, Vispo M E et al.. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients.  J Infect Dis. 2007;  196(5) 670-676
    CrossrefPubMedGoogle Scholar
  • 68 Dalton H R, Fellows H J, Stableforth W et al.. The role of hepatitis E virus testing in drug-induced liver injury.  Aliment Pharmacol Ther. 2007;  26(10) 1429-1435
    CrossrefPubMedGoogle Scholar
  • 69 Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver.  Hepatology. 2005;  41(4) 690-695
    CrossrefPubMedGoogle Scholar
  • 70 Chalasani N, Aljadhey H, Kesterson J, Murray M D, Hall S D. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity.  Gastroenterology. 2004;  126(5) 1287-1292
    CrossrefPubMedGoogle Scholar
  • 71 Vuppalanchi R, Teal E, Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes.  Am J Med Sci. 2005;  329(2) 62-65
    CrossrefPubMedGoogle Scholar
  • 72 Tarantino G, Conca P, Basile V et al.. A prospective study of acute drug-induced liver injury in patients suffering from nonalcoholic fatty liver disease.  Hepatol Res. 2007;  37(6) 410-415
    PubMedGoogle Scholar
  • 73 Rutherford A, Davern T, Hay J E Acute Liver Failure Study Group et al. Influence of high body mass index on outcome in acute liver failure.  Clin Gastroenterol Hepatol. 2006;  4(12) 1544-1549
    CrossrefPubMedGoogle Scholar

Naga ChalasaniM.D. F.A.C.G. 

Professor and Director, Division of Gastroenterology and Hepatology, Indiana University School of Medicine

RG 4100, 1050 Wishard Boulevard, Indianapolis, IN 46202

Email: nchalasa@iupui.edu